Form4insider filings, from the source

SEC Form 4 · accession 0001179110-18-014138

ENDOCYTE INC · ECYT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Beth Taylor
Officer — VP Finance & Chief Acctg Offcr
Period of report
Dec 17, 2018
Accepted (ET)
Dec 19, 2018 · 4:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001235007

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockDec 17, 2018M16,073$3.55A72,414D
Common StockDec 17, 2018M5,500$9.86A77,914D
Common StockDec 17, 2018M9,000$5.10A86,914D
Common StockDec 17, 2018M3,750$3.18A90,664D
Common StockDec 17, 2018M9,531$3.21A100,195D
Common StockDec 17, 2018M5,000$2.16A105,195D
Common StockF1Dec 17, 2018G2,500$0.00D102,695D
Common StockF2Dec 17, 2018G1,250$0.00D101,445D
Common StockF7Dec 19, 2018G3,186$0.00D98,259D
Common StockF2Dec 17, 2018G1,250$0.00A1,250IBy daughter

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock option (right to buy)F3$3.55Dec 17, 2018M16,073D—Feb 28, 2022Common Stock16,0730D
Stock option (right to buy)F3$9.86Dec 17, 2018M5,500D—Feb 19, 2023Common Stock5,5009,132D
Stock option (right to buy)F3$5.10Dec 17, 2018M9,000D—Feb 4, 2025Common Stock9,0000D
Stock option (right to buy)F4$3.18Dec 17, 2018M3,750D—Feb 4, 2026Common Stock3,7503,750D
Stock option (right to buy)F5$3.21Dec 17, 2018M9,531D—Aug 18, 2026Common Stock9,53112,969D
Stock option (right to buy)F6$2.16Dec 17, 2018M5,000D—Feb 2, 2027Common Stock5,00015,000D

Explanation of responses